| Trial ID: | L0109 |
| Source ID: | NCT00252499
|
| Associated Drug: |
Rosiglitazone
|
| Title: |
Insulin Resistance in Non-alcoholic Fatty Liver Disease
|
| Acronym: |
--
|
| Status: |
Terminated
|
| Study Results: |
Has Results
|
| Results: |
https://ClinicalTrials.gov/show/NCT00252499/results
|
| Conditions: |
Fatty Liver|Insulin Resistance
|
| Interventions: |
Drug: rosiglitazone|Drug: fenofibrate|Drug: placebo for rosiglitazone|Drug: placebo for fenofibrate
|
| Outcome Measures: |
Liver/Spleen Ratio at 6 Months|Change in Alanine Aminotransferase (ALT) Levels From Baseline to 6 Months|Change in the Liver Spleen Ratio by CT Scan From Baseline to 6 Months as a Measure of Fat in the Liver|Change in Peripheral Insulin Sensitivity From Baseline to 6 Months|Changes in Intra-abdominal Fat Area From Baseline to 6 Months|Change in Hepatic Insulin Sensitivity From Baseline to 6 Months
|
| Sponsor/Collaborators: |
US Department of Veterans Affairs|VA Office of Research and Development
|
| Gender: |
All
|
| Age: |
18 Years to 80 Years ?? (Adult, Older Adult)
|
| Phases: |
Not applicable
|
| Enrollment: |
13
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Basic Science
|
| Start Date: |
October 2005
|
| Completion Date: |
August 2010
|
| Results First Posted: |
April 11, 2014
|
| Last Update Posted: |
August 20, 2014
|
| Locations: |
VA Puget Sound Health Care System, Seattle, Seattle, Washington, United States
|
| URL: |
https://ClinicalTrials.gov/show/NCT00252499
|
